

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
28 July 2005 (28.07.2005)

PCT

(10) International Publication Number  
**WO 2005/067921 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/366**,  
31/40, 31/045, A61P 3/00

(21) International Application Number:  
PCT/IN2005/000024

(22) International Filing Date: 19 January 2005 (19.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
99/DEL/2004 20 January 2004 (20.01.2004) IN

(71) Applicant (for all designated States except US):  
**PANACEA BIOTEC LTD.**, [IN/IN]; B-1 Extn./A-27,  
Mohan Co-operative Industrial Estate, Mathura Road,  
New Delhi - 110 044 (IN).

(72) Inventors: **JINDAL, Kour, Chand**; Panacea Biotec Ltd,  
B-1 Extn./A-27, Mohan Co-operative Industrial Estate,  
Mathura Road, New Delhi - 110 044 (IN). **SINGH,**  
**Sukhjeet**; Panacea Biotec Ltd, B-1 Extn./A-27, Mohan  
Co-operative Industrial Estate, Mathura Road, New Delhi  
- 110 044 (IN).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **JAIN, Rajesh** [IN/IN];  
Panacea Biotec Ltd, B-1 Extn./A-27, Mohan Co-operative  
Industrial Estate, Mathura Road, New Delhi - 110 044 (IN).

(74) Agent: **GUPTA, Bhartee**; Panacea Biotec Ltd, B-1  
Extn./A-27, Mohan Co-operative Industrial Estate,  
Mathura Road, New Delhi - 110 044 (IN).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,

KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,  
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,  
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,  
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA,  
ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,  
NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,  
BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,  
HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

#### Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING HIGHER PRIMARY ALIPHATIC ALCOHOLS AND HMG  
COA REDUCTASE INHIBITOR AND PROCESS OF PREPARATION THEREOF

(57) Abstract: A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from (24) to (39)  
carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and  
phenolic compounds, and HMG CoA reductase inhibitor, its salts, analogs or derivatives thereof, preferably statins, optionally with  
pharmaceutically acceptable excipients, and process of preparation of such composition is provided. Also provided are method of  
treatment and use of such composition for reducing abnormal lipid parameters associated with hyperlipidemia.



WO 2005/067921 A1